Kathleen Gallagher

In April 2021, Kathleen Gallagher joined Avidity Biosciences as the Senior Vice President of Corporate Communications and Investor Relations. Ms. Gallagher brings to Avidity over 15 years of experience leading communications and investor relations in preclinical to commercial stage companies. Most recently, Ms. Gallagher lead the communications and investor relations function through the launch of two rare disease medicines at Akcea Therapeutics, Inc. Prior to that, she was at Merrimack Pharmaceuticals, Inc. where she played an integral role in multiple financing rounds, including its initial public offering, and led corporate communications through the launch of the company’s oncology medicine. Ms. Gallagher has a B.S. in English from Boston University.